Effectiveness of tolvaptan on renal replacement therapy in patients with autosomal dominant polycystic kidney disease: a retrospective cohort study from the TriNetX global collaborative network

Effectiveness of tolvaptan on renal replacement therapy in patients with autosomal dominant polycystic kidney disease: a retrospective cohort study from the TriNetX global collaborative network

Background and hypothesis Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a major genetic contributor to end-stage kidney disease (ESKD). Current evidence on tolvaptan primarily focuses on slowing estimated glomerular filtration rate (eGFR) decline and kidney volume growth. However, direct c...

Full description

Saved in:
Bibliographic Details
Main Authors: Ming-Ju Wu, Cheng-Hsu Chen, Shang-Feng Tsai
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Renal Failure
Subjects:
Tolvaptan
autosomal dominant polycystic kidney disease (ADPKD)
end-stage kidney disease (ESKD)
hemodialysis
mortality
Online Access:https://www.tandfonline.com/doi/10.1080/0886022X.2024.2412721
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items